MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Embecta Corp

Closed

SectorHealthcare

10.26 6.32

Overview

Share price change

24h

Current

Min

9.48

Max

10.37

Key metrics

By Trading Economics

Income

50M

24M

Sales

-2.9M

259M

P/E

Sector Avg

10.978

50.291

EPS

0.7

Dividend yield

6.14

Profit margin

9.073

Employees

2,000

EBITDA

24M

63M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+84.13% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

6.14%

2.40%

Next Earnings

8 Aug 2025

Next Dividend date

12 Sept 2025

Next Ex Dividend date

26 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-169M

571M

Previous open

3.94

Previous close

10.26

News Sentiment

By Acuity

50%

50%

163 / 380 Healthcare

Embecta Corp Chart

Past performance is not a reliable indicator of future results.

Related News

1 Jul 2025, 23:09 UTC

Earnings

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 Jul 2025, 19:16 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 Jul 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 Jul 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 Jul 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 Jul 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 Jul 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

James Hardie Completes Acquisition of AZEK

1 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 Jul 2025, 20:24 UTC

Earnings

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 Jul 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 Jul 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 Jul 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 Jul 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 Jul 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 Jul 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 Jul 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 Jul 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 Jul 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 Jul 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 Jul 2025, 17:01 UTC

Acquisitions, Mergers, Takeovers

Danone Completed Acquisition of Majority Stake in Kate Farms

1 Jul 2025, 16:55 UTC

Earnings

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 Jul 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 Jul 2025, 16:25 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jul 2025, 15:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 Jul 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Jul 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 Jul 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 Jul 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Comparison

Price change

Embecta Corp Forecast

Price Target

By TipRanks

84.13% upside

12 Months Forecast

Average 17.75 USD  84.13%

High 25 USD

Low 13 USD

Based on 4 Wall Street analysts offering 12 month price targets forEmbecta Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

1

Buy

2

Hold

1

Sell

Sentiment

By Acuity

163 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.